Regenicin Inc.
Regenicin, Inc. focuses on developing and commercializing the technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company's products are used to restore the qualities of hea… Read more
Regenicin Inc. (RGIN) - Total Liabilities
Latest total liabilities as of March 2023: $18.07 Million USD
Based on the latest financial reports, Regenicin Inc. (RGIN) has total liabilities worth $18.07 Million USD as of March 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regenicin Inc. - Total Liabilities Trend (2008–2022)
This chart illustrates how Regenicin Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Regenicin Inc. Competitors by Total Liabilities
The table below lists competitors of Regenicin Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gemfields Plc
LSE:GEM
|
UK | GBX206.14 Million |
|
The Marketing Alliance Inc
PINK:MAAL
|
USA | $7.44 Million |
|
SINO LAND CO
BE:SNO
|
Germany | €14.03 Billion |
|
Flexpoint Sensor Systems Inc
PINK:FLXT
|
USA | $5.34 Million |
Liability Composition Analysis (2008–2022)
This chart breaks down Regenicin Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regenicin Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regenicin Inc. (2008–2022)
The table below shows the annual total liabilities of Regenicin Inc. from 2008 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-09-30 | $5.61 Million | +8.58% |
| 2021-09-30 | $5.17 Million | +20.45% |
| 2020-09-30 | $4.29 Million | +14.96% |
| 2019-09-30 | $3.73 Million | +22.13% |
| 2018-09-30 | $3.06 Million | +20.85% |
| 2017-09-30 | $2.53 Million | +38.37% |
| 2016-09-30 | $1.83 Million | -18.71% |
| 2015-09-30 | $2.25 Million | -48.93% |
| 2014-09-30 | $4.40 Million | +3.94% |
| 2013-09-30 | $4.24 Million | +19.31% |
| 2012-09-30 | $3.55 Million | +141.88% |
| 2011-09-30 | $1.47 Million | +76.94% |
| 2010-09-30 | $829.54K | +4927.49% |
| 2009-09-30 | $16.50K | +200.00% |
| 2008-09-30 | $5.50K | -- |